Personalis (PSNL) announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of cancer recurrence in breast cancer patients. This milestone marks an important step forward in cancer surveillance, offering a powerful tool for doctors and breast cancer patients. Medicare beneficiaries with stage II and III breast cancer, including the three major subtypes HR+/HER2-, HER2+ and triple-negative breast cancer, will now have coverage for recurrence monitoring with NeXT Personal for up to six years in the surveillance setting.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL: